Table 2.
Adverse events
| Age ≥65 (n = 37) | Age <65 (n = 24) | |
|---|---|---|
| Cerebellar infarctiona | 1 (2.7) | |
| Speech disordera | 1 (2.7) | |
| Nasopharyngitis | 1 (2.7) | |
| Anxiety disorder | 1 (2.7) | |
| Choking sensation | 1 (4.2) | |
| Increased hemosputum | 1 (4.2) | |
| Pneumoniaa | 1 (2.7) | 1 (4.2) |
| Palpitation | 1 (4.2) | |
| Malignant lymphomaa | 1 (4.2) | |
| Rash (right forearm) | 1 (4.2) | |
| Epigastric pain | 1 (2.7) | |
| Abdominal discomfort | 1 (2.7) | |
| Gastroenteritis | 1 (2.7) | |
| Back pain | 2 (8.3) | |
| Lumbar discomfort | 2 (8.3) | |
| Ischial pain | 1 (4.2) | |
| Cystitis | 1 (2.7) | |
| Leukocytopenia | 1 (4.2) | |
| Elevated CRP | 2 (8.3) | |
| Elevated ESR | 1 (4.2) | |
| Total | 9 (24.3) | 15 (62.5) |
The values shown denote the number (%) of patients
aSerious adverse event